Dermapharm Holding SE
DUS:DMP

Watchlist Manager
Dermapharm Holding SE Logo
Dermapharm Holding SE
DUS:DMP
Watchlist
Price: 38.25 EUR 2.27% Market Closed
Market Cap: 4.1B EUR

Operating Margin
Dermapharm Holding SE

18.7%
Current
20%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
18.7%
=
Operating Profit
217m
/
Revenue
1.2B

Operating Margin Across Competitors

No Stocks Found

Dermapharm Holding SE
Glance View

Market Cap
4.1B EUR
Industry
Pharmaceuticals

In the bustling world of pharmaceuticals, Dermapharm Holding SE stands as a noteworthy player, crafting a narrative of strategic growth and innovation. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm presents itself as a vertically integrated pharmaceutical company whose operations stretch from development and production to marketing and distribution. This integration allows them to maintain control over their value chain, ensuring efficiency and quality across diverse product lines. Dermapharm's portfolio spans over 900 active pharmaceutical ingredients, health products, and medical devices, fortified through keenly orchestrated acquisitions that enhance their market presence and product offerings. Such strategic steps enable Dermapharm to leverage established brands while venturing into new sectors, reinforcing its reputation as a dynamic force in the pharmaceutical landscape. Dermapharm primarily generates revenue by capitalizing on dermatological products, allergy treatments, systemic corticosteroids, and vitamin supplements. By addressing a broad spectrum of chronic and everyday health conditions, they serve both niche and mass-market demands across Europe. Dermapharm’s distinctive approach combines robust in-house research and development with targeted acquisitions, such as their acquisition of the Dr. Loges-Schuten pharmaceutical company, broadening their reach into phyto-pharmaceuticals and other sectors. Additionally, Dermapharm collaborates with partners to penetrate new geographical markets, thereby diversifying their revenue streams. Such initiatives underscore the company's agility and strategic foresight, ensuring sustained growth in a competitive industry.

DMP Intrinsic Value
50.45 EUR
Undervaluation 24%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
18.7%
=
Operating Profit
217m
/
Revenue
1.2B
What is the Operating Margin of Dermapharm Holding SE?

Based on Dermapharm Holding SE's most recent financial statements, the company has Operating Margin of 18.7%.

Back to Top